Italy’s Recordati Said to Weigh Options Amid Asian Interest

  • Family-owned drugmaker has market value of 6.1 billion euros
  • Recordati may attract interest from other pharmaceutical firms

Family-owned Italian drugmaker Recordati SpA is exploring strategic options that may lead to a sale amid potential interest from Asian buyers, according to people with knowledge of the matter.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.